| Mechanisms of resistance to EGFR-targeted drugs: lung cancer F Morgillo, CM Della Corte, M Fasano, F Ciardiello ESMO open 1 (3), e000060, 2016 | 436 | 2016 |
| Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy M Fasano, CM Della Corte, F Papaccio, F Ciardiello, F Morgillo Journal of Thoracic Oncology 10 (8), 1133-1141, 2015 | 272 | 2015 |
| SMO gene amplification and activation of the hedgehog pathway as novel mechanisms of resistance to anti-epidermal growth factor receptor drugs in human lung cancer CM Della Corte, C Bellevicine, G Vicidomini, D Vitagliano, U Malapelle, ... Clinical cancer research 21 (20), 4686-4697, 2015 | 121 | 2015 |
| Diagnostic salivary tests for SARS-CoV-2 L Azzi, V Maurino, A Baj, M Dani, A d’Aiuto, M Fasano, M Lualdi, F Sessa, ... Journal of dental research 100 (2), 115-123, 2021 | 111 | 2021 |
| Role and targeting of anaplastic lymphoma kinase in cancer CM Della Corte, G Viscardi, R Di Liello, M Fasano, E Martinelli, T Troiani, ... Molecular cancer 17, 1-9, 2018 | 95 | 2018 |
| Heme-based catalytic properties of human serum albumin P Ascenzi, A Di Masi, G Fanali, M Fasano Cell death discovery 1 (1), 1-7, 2015 | 79 | 2015 |
| Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: A multicentre, open-label phase I–II study of metformin with erlotinib in second-line … F Morgillo, M Fasano, CM Della Corte, FC Sasso, F Papaccio, G Viscardi, ... ESMO open 2 (2), e000132, 2017 | 70 | 2017 |
| Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study C Gridelli, F Morgillo, A Favaretto, F De Marinis, A Chella, G Cerea, ... Annals of oncology 22 (7), 1528-1534, 2011 | 64 | 2011 |
| Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells CM Della Corte, V Ciaramella, C Di Mauro, MD Castellone, F Papaccio, ... Oncotarget 7 (4), 4265, 2016 | 63 | 2016 |
| Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: A prospective multicentre study L Rinaldi, A Perrella, M Guarino, M De Luca, G Piai, N Coppola, ... Journal of Translational Medicine 17, 1-10, 2019 | 62 | 2019 |
| Immunotherapy for head and neck cancer: Present and future M Fasano, CM Della Corte, R Di Liello, G Viscardi, F Sparano, ... Critical reviews in oncology/hematology 174, 103679, 2022 | 58 | 2022 |
| Head and neck cancer: The role of anti-EGFR agents in the era of immunotherapy M Fasano, CM Della Corte, G Viscardi, R Di Liello, F Paragliola, ... Therapeutic advances in medical oncology 13, 1758835920949418, 2021 | 49 | 2021 |
| Is neuromelanin changed in Parkinson’s disease? Investigations by magnetic spectroscopies M Fasano, B Bergamasco, L Lopiano Journal of neural transmission 113, 769-774, 2006 | 47 | 2006 |
| Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer F Iovino, F Ferraraccio, M Orditura, G Antoniol, F Morgillo, T Cascone, ... Cancer investigation 26 (3), 250-255, 2008 | 45 | 2008 |
| Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer M Fasano, CM Della Corte, R Califano, A Capuano, T Troiani, E Martinelli, ... Expert Opinion on Investigational Drugs 23 (6), 809-821, 2014 | 37 | 2014 |
| The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion A Fiorelli, F Morgillo, M Fasano, G Vicidomini, VG Di Crescenzo, ... Interactive cardiovascular and thoracic surgery 16 (3), 263-269, 2013 | 35 | 2013 |
| Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study R Di Liello, V Ciaramella, G Barra, M Venditti, CM Della Corte, F Papaccio, ... ESMO open 4 (4), e000536, 2019 | 34 | 2019 |
| Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab G Martini, D Ciardiello, M Dallio, V Famiglietti, L Esposito, CMD Corte, ... International Journal of Cancer 151 (3), 473-480, 2022 | 33 | 2022 |
| Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non–small-cell lung cancer M Di Maio, NB Leighl, C Gallo, R Feld, F Ciardiello, C Butts, P Maione, ... Journal of Thoracic Oncology 7 (12), 1830-1844, 2012 | 33 | 2012 |
| Role of HGF–MET signaling in primary and acquired resistance to targeted therapies in cancer CM Della Corte, M Fasano, F Papaccio, F Ciardiello, F Morgillo Biomedicines 2 (4), 345-358, 2014 | 31 | 2014 |
Laura GiannettaNiguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milan, Italy在 ospedaleniguarda.it 的电子邮件经过验证
Laura GiannettaNiguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milan, Italy在 ospedaleniguarda.it 的电子邮件经过验证